The US Food and Drug Administration has granted 510(k) premarket notification clearance for eliminating the requirement for a nasal cannula during a MATRx plus sleep theragnostic test.

This change to Zephyr Sleep Technology’s MATRx plus makes setting up the take-home sleep appliance treatment planning test simpler for the patient and easier for the dental team to dispense. MATRx plus Treatment Planning, clinicians can determine WHO can be treated with oral appliance therapy and HOW to configure the oral appliance for therapeutic effectiveness.With only a single fingertip pulse oximetry probe needed for testing, patients may have a more comfortable sleep during their sleep study and therapy test.

All existing MATRx plus users who are Connected Program subscribers will receive this innovation, at no additional charge, as all software updates are included within the subscription.

“Over 375 dentist offices in North America now use MATRx plus. Dentists and their teams tell us it’s all about the importance of delivering a better patient experience. With this latest innovation, we’ve made a simple test and workflow even easier,” says Paul Cataford, CEO & co-founder, Zephyr, in a release.

“This is breakthrough technology that improves patient comfort, reduces nighttime interruptions and without compromising predictive accuracy. This innovation is extraordinarily important to the advancement of predictive oral appliance therapy, which can be nearly 100% effective when using MATRx plus,” says John E. Remmers, MD, chief medical officer and founder of Zephyr, in a release.